Financial Analysis: GoodRx (NASDAQ:GDRX) & Paranovus Entertainment Technology (NASDAQ:PAVS)

Paranovus Entertainment Technology (NASDAQ:PAVS) and GoodRx (NASDAQ:GDRX) are both small-cap multi-sector conglomerates companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, valuation, earnings, analyst recommendations, profitability, risk and dividends.

Valuation and Earnings

This table compares Paranovus Entertainment Technology and GoodRx”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Paranovus Entertainment Technology	$6.54 million	1.51	-$10.13 million	N/A	N/A
GoodRx	$792.32 million	2.25	-$8.87 million	$0.05	92.80

GoodRx has higher revenue and earnings than Paranovus Entertainment Technology.

Institutional & Insider Ownership

0.2% of Paranovus Entertainment Technology shares are owned by institutional investors. Comparatively, 63.8% of GoodRx shares are owned by institutional investors. 15.6% of Paranovus Entertainment Technology shares are owned by company insiders. Comparatively, 4.2% of GoodRx shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Paranovus Entertainment Technology and GoodRx’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Paranovus Entertainment Technology	N/A	N/A	N/A
GoodRx	-2.05%	5.35%	2.51%

Analyst Recommendations

This is a summary of current recommendations and price targets for Paranovus Entertainment Technology and GoodRx, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Paranovus Entertainment Technology	0	0	0	0	0.00
GoodRx	0	3	6	1	2.80

GoodRx has a consensus price target of $8.18, suggesting a potential upside of 76.19%. Given GoodRx’s stronger consensus rating and higher possible upside, analysts clearly believe GoodRx is more favorable than Paranovus Entertainment Technology.

Risk and Volatility

Paranovus Entertainment Technology has a beta of -0.03, meaning that its stock price is 103% less volatile than the S&P 500. Comparatively, GoodRx has a beta of 1.25, meaning that its stock price is 25% more volatile than the S&P 500.

Summary

GoodRx beats Paranovus Entertainment Technology on 11 of the 13 factors compared between the two stocks.

About Paranovus Entertainment Technology

Paranovus Entertainment Technology Ltd. engages in the research, development, manufacture, and sale of nutraceutical and dietary supplement products in the People's Republic of China and internationally. The company's product category includes lucidum spore powders, cordyceps mycelia, Ejiao products, American ginseng products, other traditional Chinese herbal and animal extracts, vitamins, minerals, and amino acids. It also offers product marketing and e-commerce agency operation services under the Happy Buy platform to small and middle size businesses; and e-commerce solutions, internet information, and advertising services to the online stores or manufactures. In addition, the company provides secure transaction environment, automobile procurement, and financial services for automobile manufacturers under the Taochejun automobile sales platform. It sells its products through distributors, large-scale chain drugstores, malls, and supermarkets under the Happiness brand. The company was formerly known as Happiness Development Group Limited and changed its name to Paranovus Entertainment Technology Ltd. in March 2023. The company was founded in 2004 and is headquartered in Nanping, the People's Republic of China.

About GoodRx

GoodRx Holdings, Inc., together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices. It also offers other healthcare products and services, including subscriptions, and pharma manufacturer solutions, as well as telehealth services through the GoodRx Care platform. It serves pharmacy benefit managers who manage formularies and prescription transactions, including establishing pricing between consumers and pharmacies. The company was founded in 2011 and is headquartered in Santa Monica, California.